C M C Oude Ophuis1, C Verhoef2, P Rutkowski3, B W E M Powell4, J A van der Hage5, P A M van Leeuwen6, C A Voit7, A Testori8, C Robert9, H J Hoekstra10, D J Grünhagen11, A M M Eggermont12, A C J van Akkooi13. 1. Department of Surgical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. Electronic address: c.oudeophuis@erasmusmc.nl. 2. Department of Surgical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. Electronic address: c.verhoef@erasmusmc.nl. 3. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, ul. W.K. Roentgena 5, 02-781 Warsaw, Poland. Electronic address: rutkowskip@coi.waw.pl. 4. Melanoma Unit, St. George's Foundation University Hospital, Blakshaw Road, Tooting, London SW17 0QT, United Kingdom. Electronic address: bpowell@sgul.ac.uk. 5. Department of Surgery, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address: j.vd.hage@nki.nl. 6. Department of Surgical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Electronic address: pam.vleeuwen@vumc.nl. 7. Department of Dermatology, Charité, University of Medicine Berlin, Charitéplatz 1, 10117 Berlin, Germany. 8. Division of Dermato Oncological Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address: alessandro.testori@ieo.it. 9. Department of Dermatology, Cancer Institute Gustave Roussy, 114 rue Édouard-Vaillant, 94805 Villejuif, France. Electronic address: caroline.robert@igr.fr. 10. Department of Surgical Oncology, Groningen University, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Electronic address: h.j.hoekstra@umcg.nl. 11. Department of Surgical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. Electronic address: d.grunhagen@erasmusmc.nl. 12. Cancer Institute Gustave Roussy, 114 rue Édouard-Vaillant, 94805 Villejuif, France. Electronic address: alexander.eggermont@igr.fr. 13. Department of Surgery, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address: a.v.akkooi@nki.nl.
Abstract
BACKGROUND: Worldwide, sentinel node biopsy (SNB) is the recommended staging procedure for stage I/II melanoma. Most melanoma guidelines recommend re-excision plus SNB as soon as possible after primary excision. To date, there is no evidence to support this timeframe. AIM: To determine melanoma specific survival (MSS) for time intervals between excisional biopsy and SNB in SNB positive patients. METHODS: Between 1993 and 2008, 1080 patients were diagnosed with a positive SNB in nine Melanoma Group centers. We selected 1015 patients (94%) with known excisional biopsy date. Time interval was calculated from primary excision until SNB. Kaplan-Meier estimated MSS was calculated for different cutoff values. Multivariable analysis was performed to correct for known prognostic factors. RESULTS: Median age was 51 years (Inter Quartile Range (IQR) 40-62 years), 535 (53%) were men, 603 (59%) primary tumors were located on extremities. Median Breslow thickness was 3.00 mm (IQR 1.90-4.80 mm), 442 (44%) were ulcerated. Median follow-up was 36 months (IQR 20-62 months). Median time interval was 47 days (IQR 32-63 days). Median Breslow thickness was equal for both <47 days and ≥47 days interval: 3.00 mm (1.90-5.00 mm) vs 3.00 mm (1.90-4.43 mm) (p = 0.402). Sentinel node tumor burden was significantly higher in patients operated ≥47 days (p = 0.005). Univariate survival was not significantly different for median time interval. Multivariable analysis confirmed that time interval was no independent prognostic factor for MSS. CONCLUSIONS: Time interval from primary melanoma excision until SNB was no prognostic factor for MSS in this SNB positive cohort. This information can be used to counsel patients.
BACKGROUND: Worldwide, sentinel node biopsy (SNB) is the recommended staging procedure for stage I/II melanoma. Most melanoma guidelines recommend re-excision plus SNB as soon as possible after primary excision. To date, there is no evidence to support this timeframe. AIM: To determine melanoma specific survival (MSS) for time intervals between excisional biopsy and SNB in SNB positive patients. METHODS: Between 1993 and 2008, 1080 patients were diagnosed with a positive SNB in nine Melanoma Group centers. We selected 1015 patients (94%) with known excisional biopsy date. Time interval was calculated from primary excision until SNB. Kaplan-Meier estimated MSS was calculated for different cutoff values. Multivariable analysis was performed to correct for known prognostic factors. RESULTS: Median age was 51 years (Inter Quartile Range (IQR) 40-62 years), 535 (53%) were men, 603 (59%) primary tumors were located on extremities. Median Breslow thickness was 3.00 mm (IQR 1.90-4.80 mm), 442 (44%) were ulcerated. Median follow-up was 36 months (IQR 20-62 months). Median time interval was 47 days (IQR 32-63 days). Median Breslow thickness was equal for both <47 days and ≥47 days interval: 3.00 mm (1.90-5.00 mm) vs 3.00 mm (1.90-4.43 mm) (p = 0.402). Sentinel node tumor burden was significantly higher in patients operated ≥47 days (p = 0.005). Univariate survival was not significantly different for median time interval. Multivariable analysis confirmed that time interval was no independent prognostic factor for MSS. CONCLUSIONS: Time interval from primary melanoma excision until SNB was no prognostic factor for MSS in this SNB positive cohort. This information can be used to counsel patients.
Authors: Daniel W Nelson; Stacey Stern; David E Elashoff; Robert Elashoff; John F Thompson; Nicola Mozzillo; Omgo E Nieweg; Harald J Hoekstra; Alistair J Cochran; Mark B Faries Journal: J Am Coll Surg Date: 2017-06-28 Impact factor: 6.113
Authors: Alexander M M Eggermont; Domenico Bellomo; Suzette M Arias-Mejias; Enrica Quattrocchi; Sindhuja Sominidi-Damodaran; Alina G Bridges; Julia S Lehman; Tina J Hieken; James W Jakub; Dennis H Murphree; Mark R Pittelkow; Jason C Sluzevich; Mark A Cappel; Sanjay P Bagaria; Charles Perniciaro; Félicia J Tjien-Fooh; Barbara Rentroia-Pacheco; Renske Wever; Martin H van Vliet; Jvalini Dwarkasing; Alexander Meves Journal: Eur J Cancer Date: 2020-10-05 Impact factor: 9.162
Authors: Enrica Quattrocchi; Sindhuja Sominidi-Damodaran; Dennis H Murphree; Alexander Meves Journal: Int J Dermatol Date: 2020-08-09 Impact factor: 2.736
Authors: Domenico Bellomo; Suzette M Arias-Mejias; Chandru Ramana; Joel B Heim; Enrica Quattrocchi; Sindhuja Sominidi-Damodaran; Alina G Bridges; Julia S Lehman; Tina J Hieken; James W Jakub; Mark R Pittelkow; David J DiCaudo; Barbara A Pockaj; Jason C Sluzevich; Mark A Cappel; Sanjay P Bagaria; Charles Perniciaro; Félicia J Tjien-Fooh; Martin H van Vliet; Jvalini Dwarkasing; Alexander Meves Journal: JCO Precis Oncol Date: 2020-04-14
Authors: M Arenbergerova; A Lallas; E Nagore; L Rudnicka; A M Forsea; M Pasek; F Meier; K Peris; J Olah; C Posch Journal: J Eur Acad Dermatol Venereol Date: 2021-04-13 Impact factor: 6.166